Harbin Medisan Pharmaceutical Co.,Ltd. (002900.SZ) released its interim report for 2025. During the reporting period, the company recorded operating revenue of 413 million yuan, representing a year-on-year decline of 21.08%. Net loss attributable to shareholders of the listed company amounted to 92.39 million yuan. Net loss attributable to shareholders of the listed company excluding non-recurring items reached 89.20 million yuan. Basic loss per share was 0.29 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments